Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

Abstract Background The treatment of metastatic breast cancer (MBC) remains a great clinical challenge as drug resistance frequently develops. Alternative agents that can overcome drug resistance would offer new therapeutic options. The primary aim of this phase II study was to evaluate the efficacy...

Full description

Bibliographic Details
Main Authors: Pin Zhang, Zhongsheng Tong, Fuguo Tian, Yongsheng Wang, Junlan Yang, Weilian Li, Lijun Di, Wei Liu, Li Tang, Rongguo Qiu, Binghe Xu
Format: Article
Language:English
Published: BMC 2016-08-01
Series:Journal of Hematology & Oncology
Subjects:
Utidelone
Metastatic breast cancer
Phase II trial
Drug resistance
Online Access:http://link.springer.com/article/10.1186/s13045-016-0297-7

Internet

http://link.springer.com/article/10.1186/s13045-016-0297-7

Similar Items